A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

NCT01194375 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Acne Vulgaris

Interventions

DRUG: Low Strength IDP-107
DRUG: High Strength IDP-107
DRUG: Placebo

Sponsor

Dow Pharmaceutical Sciences